Résistance aux analogues de nucléosides dans le traitement de l'hépatite chronique B

[1]  P. Michetti,et al.  A propos de la conférence européenne de consensus sur l'hépatite B : Genève, 13 et 14 septembre 2002 , 2003 .

[2]  Yoshiyuki Suzuki,et al.  Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. , 2002, Journal of hepatology.

[3]  Manna Zhang,et al.  Rapid detection of hepatitis B virus mutations using real‐time PCR and melting curve analysis , 2002, Hepatology.

[4]  C. Gibbs,et al.  Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks , 2002, Hepatology.

[5]  G. Papatheodoridis,et al.  Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. , 2002 .

[6]  Ruy M Ribeiro,et al.  Dynamics of hepatitis B virus infection. , 2002, Microbes and infection.

[7]  R. D. de Man,et al.  The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  C. Gibbs,et al.  Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[9]  M. Winters,et al.  Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication , 2002, Antimicrobial Agents and Chemotherapy.

[10]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study , 2001, The Lancet.

[11]  D. Mutimer.  Hepatitis B virus infection: resistance to antiviral agents. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.

[13]  T. Liang,et al.  Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. , 2001, Gastroenterology.

[14]  C. Chu,et al.  Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy , 2000, Hepatology.

[15]  C. Hunt,et al.  Clinical relevance of hepatitis B viral mutations , 2000, Hepatology.

[16]  L. Stuyver,et al.  Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy , 2000, Journal of Clinical Microbiology.

[17]  C. Gibbs,et al.  In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance , 2000, Hepatology.

[18]  F. Zoulim.  Pharmacologie des antiviraux et résistance virale aux traitements , 2000 .

[19]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[20]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[21]  E. Schiff,et al.  Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy , 1999, Hepatology.

[22]  F. Zoulim,et al.  New Antiviral Agents for the Therapy of Chronic Hepatitis B Virus Infection , 1999, Intervirology.

[23]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[24]  J. Dienstag,et al.  THERAPY WITH NUCLEOSIDE ANALOGUES FOR HEPATITIS B VIRUS INFECTION , 1999 .

[25]  C. Gibbs,et al.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro , 1998, Hepatology.

[26]  R. D. de Man,et al.  The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. , 1998, Journal of hepatology.

[27]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[28]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.

[29]  S. Schalm,et al.  Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. , 1995, Journal of hepatology.

[30]  L O Magnius,et al.  Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. , 1995, Intervirology.

[31]  A. Lok.  Treatment of chronic hepatitis B , 1994, Journal of viral hepatitis.